Therapeutics Allocation & Requests

Thank you for your role in supporting access to therapeutics in Oregon. The Oregon Health Authority (OHA) appreciates your partnership as we continue navigating the federal allocation process.

Federal Allocations

Week of July 18th:

Provider Updates

• On July 6th, 2022, the FDA updated the EUA for Paxlovid to allow for pharmacist prescribing for individual patients with certain limitations. 
  • With this recent change in the Paxlovid EUA, Oregon-licensed pharmacists now have liability immunity and scope of authority to prescribe Paxlovid under the 9th amendment of the Department of Health and Human Services Public Readiness and Emergency Preparedness Act (PREP). Pharmacy interns and technicians cannot prescribe Paxlovid under the PREP Act because the Paxlovid EUA only authorizes pharmacists to prescribe Paxlovid. Pharmacists must adhere to the EUA and the PREP Act when prescribing Paxlovid, including all documentation and patient follow-up required under the EUA and PREP Act. 

• FDA authorizes revisions to Evusheld re-dosing and Evusheld shelf life extensions.  
• Please review the updated Paxlovid EUA for updated information about drug interactions and contraindications. 
• OHA has launched the new COVID-19 Therapeutics Newsletter! Please click the link to view the July edition for COVID-19 therapeutics updates, allocation data, events and more. Our newsletters will be sent out monthly and can be found under the "Additional Resources" section on our webpages. Please feel free to share. 
• The federal government has changed the reporting cadence for Evusheld, bebtelovimab, Paxlovid, and Lagevrio (molnupiravir) to only twice per week, Mondays and Thursdays, by 11:59pm.  
• The federal government has released the Test to Treat Locator to make it easier to find Test to Treat (T2T) sites and where to send prescriptions to.
  
  • Please check the locator periodically as sites continue to be added.  
• Please join us for our new OHA Therapeutics Office Hours that will be held every Monday from 2:00pm - 2:30pm PST. The purpose of these office hours are to provide HPoP updates, best practices, and other helpful information from OHA's Logistics team on COVID-19 therapeutics processes. This is an opportunity for providers to ask questions, provide feedback, and discuss topics with other providers.  
• For additional guidance on the new ordering process, cadence, and reporting utilization, please review our Provider Operations Manual. 
• Please visit our COVID-19 Therapeutics Landing Page  for information and resources on mAbs and antivirals. 
• For all questions or inquiries, please email us at OHA.therapeutics@odhsoha.oregon.gov 

Placing Requests

• All orders are to be placed via the Health Partner Ordering Portal (HPOP).  
• If you are a new provider site and have not signed up to receive therapeutics via Oregon Health Authority, please complete the Complete the COVID-19 Therapeutics Provider Registration Survey. 

Product Case Size 

Each product has a specific case size and is outlined below. When ordering, please consider the case size and order accordingly to ensure OHA can fulfill your requests properly.  

• Evusheld - 24 cases 
• Bebtelovimab - 5 cases 
• Paxlovid - 20 courses 
• Renal Paxlovid - 5 courses 
• Lagevrio (molnupiravir) - 24 courses 

Allocation 

For information on mAbs allocation process, and to view published federal allocation amounts, please visit: OHA's Monoclonal Antibody Webpage 

For information on oral antivirals allocation process, and to view published federal allocation amounts, please visit:  OHA's Antiviral Webpage 

Cadence 

• Monday - HHS notifies Oregon of our total therapeutics allotment.

NOTE: HHS informs Oregon of  Evusheld’s total allotment monthly, every 4th Monday   

• Wednesday - Orders received by 11:59 p.m. will be allocated for the current week  
• Thursday/Friday - OHA staff will review the requests, determine allotments for each requesting site, and process via the Health Partner Ordering Portal (HPOP) by Friday.

NOTE: AmerisourceBergen anticipates shipping the products within 3-5 days of order submission. 

Utilization reporting 

Utilization reporting is a key component that HHS takes into consideration when determining each state’s allotment. Therefore, it is crucial that each site report their utilization twice a week on Mondays and Thursdays by 11:59pm, including for any product redistributed to other sites. Under-utilization in HPoP and under-reporting will affect Oregon’s future allocations. 

Track your shipment 

Once your packages are shipped by Amerisource Bergen, you can track them using Track My Shipment Tool.  

For oral antivirals shipment tracking, please visit your HPOP account and reference "Therapeutic Shipping." 

Thank you, 

Oregon Health Authority